Aarhus University Hospital Psychiatry, Aarhus, Denmark, shows in a real-world pharmacogenetic frequency study of genotypes and phenotypes among 77.684 persons a high number (72%) of at least one pharmacogenetic variant or divergent phenotype indicating the importance of pharmacogenetic panel-based genotyping.

The study also touches upon panel based genotyping could increase the clinical usefulness of PGx testing, as it was shown that 91-96% of the individuals of previously studied cohorts carried at least one actionable gene variant.  Panel-based genotyping can be executed in response to a first drug prescription, and results can be re-used for all subsequent drug prescriptions in the future.


Share this post